Key immunotherapy combinations for urothelial cancer
Matthew Galsky, MD, FASCO, Icahn School of Medicine at Mount Sinai, New York, NY, talks on the use of immunotherapy combinations for the treatment of urothelial cancer. Prof. Galsky comments on the findings of the Phase III DANUBE study (NCT02516241) of durvalumab with or without tremelimumab. This study did not show a survival benefit of durvalumab therapy in comparison to standard of care (SOC) chemotherapy in primary analysis, but demonstrated a survival benefit in patients with high PD-L1 expressing tumors in secondary analysis. Prof. Galsky also talks on the Phase III CheckMate 901 study (NCT03036098) of nivolumab in combination with ipilimumab or SOC chemotherapy versus SOC chemotherapy alone in patients with untreated inoperable or metastatic urothelial cancer. Prof. Galsky comments on the role of antibody-drug conjugates in combination with immune checkpoint inhibitors, highlighting data on pembrolizumab and enfortumab vedotin in the frontline treatment of patients with urothelial carcinoma, and discusses the role of HER2-targeted agents and multi-targeted kinase inhibitors such as sitravatinib, lenvatinib and cabozantinib. This interview took place at the virtual European Association of Urology (EAU) Virtual Meeting 2021.
-
Category
No comments found